文献速递中药与中成药合理使用中医内科

五黄制剂治疗特应性皮炎的胚胎毒性与刺激性体外测试

In vitro tests to evaluate embryotoxicity and irritation of Chinese herbal medicine (Pentaherbs formulation) for atopic dermatitis.
PubMed 文献 · J Ethnopharmacol · 2023-01-08

该研究通过胚胎干细胞试验(EST)和皮肤刺激性试验(SIT)评估五黄制剂(PHF)及其5种单味药提取物的安全性。结果显示PHF及多数单味药无胚胎毒性,但黄柏(Phellodendron chinense)呈弱胚胎毒性;所有受试药物处理后细胞活力均高于50%。结论提示PHF在体外试验中安全性初步良好,但孕妇需慎用。

要点

  • PHF及多数单味药在EST中无胚胎毒性,黄柏呈弱胚胎毒性。
  • SIT中所有受试药物处理后细胞活力均高于50%,提示无明显刺激性。
  • PHF用于孕妇特应性皮炎患者需谨慎,尤其计划妊娠或哺乳期者。

核心结论

  • 体外试验为PHF在胚胎干细胞试验和皮肤刺激模型中的安全性提供了初步证据。
  • 黄柏(Phellodendron chinense)在EST中显示弱胚胎毒性,PHF在孕妇中应谨慎使用。

研究设计与样本

  • 采用小鼠胚胎干细胞系(D3)和小鼠成纤维细胞系(3T3)进行胚胎干细胞试验(EST),培养10天后通过浓度-反应曲线评估三个终点。
  • 采用商业可用的表皮等效试剂盒(EpiDerm™)进行皮肤刺激性试验(SIT),通过MTT法获得浓度-活力曲线。
  • 5种PHF单味药提取物经色谱法确认质量。

主要发现

  • 化学鉴定确认5种受试药物提取物含有其主要活性化合物。
  • EST结果显示PHF配方及其单味药均无胚胎毒性,但黄柏(Phellodendron chinense)呈弱胚胎毒性。
  • SIT结果显示不同浓度所有受试药物处理后细胞活力均高于50%。

关键数值与推荐

  • EST评估终点包括:50%抑制D3分化为搏动心肌细胞(ID50D3)、对D3的50%细胞毒性(IC50D3)和对成纤维细胞的50%细胞毒性(IC503T3)。
  • 采用基于生物统计学的预测模型(PM)预测每种中药的胚胎毒性潜力。
  • SIT以细胞活力高于50%作为判断标准,所有受试药物均满足。

临床怎么用

  • PHF在体外试验中显示无明显胚胎毒性和刺激性,但孕妇特应性皮炎患者使用时应谨慎。
  • 对于计划妊娠或哺乳期的特应性皮炎患者,PHF的临床应用需进一步研究支持。

局限性

  • 本研究为体外试验,结果需进一步临床研究验证。
  • PHF的安全性数据尚不充分,尤其缺乏孕妇和哺乳期人群的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Atopic dermatitis (AD) is a common chronic inflammatory skin disorder and its prevalence is increasing in the last few decades. No treatment can cure the condition. Pregnancy often worsens the clinical manifestation. There are considerable interests in Chinese Herbal Medicine (CHM) as an alternative treatment for AD. A well tolerated CHM formula (Pentaherbs formulation, PHF) has been proven efficacious in improving life quality and reducing topical corticosteroid use in children with moderate-to-severe AD. However, safety data of PHF are not available. AIM OF THE STUDY: Our study aimed to evaluate the safety of PHF and its 5 individual herbal extracts, including embryotoxicity by Embryonic Stem Cell Test (EST) and irritation by Skin Irritation Test (SIT). MATERIALS AND METHODS: Quality of 5 herbal extracts of PHF was confirmed by chromatography. In EST, mouse embryonic stem cell line (D3) and mouse fibroblast cell line (3T3) were used to study potential embryotoxicity. Three endpoints were assessed by concentration-response curves after 10 days' culture: 50% inhibition of D3 differentiation into beating cardiomyocytes (ID50D3), 50% cytotoxic effects on D3 (IC50D3) and on fibroblasts (IC503T3). A biostatistically based prediction model (PM) was applied to predict the embryotoxic potentials of each CHM. In SIT, epidermis equivalent commercially available kits (EpiDerm™) were used, and concentration-viability curves were obtained by MTT assay to detect skin irritations of each CHM. RESULTS: Chemical authentication confirmed that 5 test herbal extracts contained their main active compounds. EST results indicated that the formula PHF and its individual CHMs were non-embryotoxic, except one CHM, Amur Corktree Bark (Huang Bai, Phellodendron chinense C.K.Schneid), was weakly embryotoxic. SIT results showed that cell viability was above 50% after treatment with different concentrations of all tested CHMs. CONCLUSIONS: Our in vitro tests provided preliminary evidence for safety of the formula PHF in embryonic stem cell test and skin irritation model, but PHF shall be cautiously used in pregnant women with AD. Further studies are needed to support its clinical application as an alternative treatment for AD, especially to the patients who plan for pregnancy or at lactation stages.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li L, Mou X, Xie H, et al. In vitro tests to evaluate embryotoxicity and irritation of Chinese herbal medicine (Pentaherbs formulation) for atopic dermatitis. J Ethnopharmacol. 2023. PMID: 36632857. doi:10.1016/j.jep.2023.116149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。